Proliferation of mammalian cardiomyocytes stops during the first weeks after birth, preventing the heart from regenerating after injury. Recently, several studies have indicated that induction of cardiomyocyte proliferation can be utilized to regenerate the mammalian heart. Thus, it is important to identify novel factors that can induce proliferation of cardiomyocytes. Here, we determine the effect of TNF-related weak inducer of apoptosis (TWEAK) on cardiomyocytes, a cytokine known to regulate proliferation in several other cell types.
Introduction
Heart disease results in the loss of cardiomyocytes and is among the leading causes of death worldwide. 1 Conventional treatment regimens of heart disease are limited in their effectiveness as they fail to correct the loss of cardiomyocytes. Therefore, it is important to provide a source of new cardiomyocytes to sufficiently repair the heart. Recently, our laboratory has shown that proliferation in differentiated cardiomyocytes can be achieved as one possibility to increase the number of cardiomyocytes after injury. 2 Furthermore, subsequent studies have suggested that the induction of proliferation in vivo can promote heart regeneration. 3 -5 In the present study, we investigated the effect of TNF-related weak inducer of apoptosis (TWEAK) on post-natal rat cardiomyocytes. TWEAK has been shown to regulate proliferation of several cell types including liver oval cells, salivary epithelial cells, skeletal muscle myoblasts as well as kidney mesangial cells, podocytes, and tubular cells. 6 -10 TWEAK is a member of the TNF-a growth factor family. It is produced as a Type II transmembrane glycoprotein and is processed into the 156 amino acid soluble cytokine. 11 It has diverse biological functions in processes like inflammation, angiogenesis, and cell survival. TWEAK mediates these processes through the fibroblast growth factor-inducible molecule 14 (FN14) receptor, 12, 13 a tightly regulated and inducible receptor that has been suggested to signal through a variety of downstream signalling cascades. 14 -17 Here, we demonstrate that TWEAK is a positive regulator of cardiomyocyte proliferation acting via its receptor FN14. TWEAK stimulation of neonatal rat cardiomyocytes activated the extracellular signal-regulated kinases (ERK) and PI3 kinase signalling pathways and inhibited glycogen synthase kinase (GSK)-3beta leading to proliferation. Interfering with FN14 receptor signalling or the downstream signalling pathways utilizing blocking antibodies, siRNAs or small molecule inhibitors inhibited TWEAK-induced DNA synthesis. In contrast to neonatal cardiomyocytes, TWEAK stimulation did not induce DNA synthesis in adult cardiomyocytes. This might be due to downregulation of FN14 expression after birth, because overexpression of FN14 enabled efficient induction of DNA synthesis in adult cardiomyocytes after TWEAK stimulation.
Methods

Animals and cardiomyocyte isolation
The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) . Animal experiments were approved by the local Committee for Care and Use of Laboratory Animals (Regierungspräsidium Darmstadt, Gen. Nr. B 2/202). Ventricular cardiomyocytes from embryonic day 17 (E17), 3-day-old (P3) and 10-to 12-week-old (adult) Sprague Dawley rats were isolated and cultured as described.
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Stimulation of cardiomyocytes
Neonatal cardiomyocytes from post-natal day 3 were initially cultured for 48 h in the presence of 20 mM cytosine b-D-arabinofuranoside (araC; Sigma) and 5% horse serum to prevent proliferation of nonmyocytes. Afterwards, cells were washed and stimulated once with TWEAK recombinant protein (Biolegend) and subjected at indicated times to BrdU (5-bromo-2 0 -deoxyuridine), H3P (phosphorylated histone H3), and Aurora B analyses. Adult cardiomyocytes were isolated and infected with FN14-Myc or GFP adenoviruses at the following day. Cells were washed and stimulated with TWEAK 48 h after virus infection. Stimulation was repeated every 3 days. The incubation with affinity purified anti-human/mouse FN14/TWEAK receptor antibody ITEM-2, mouse IgA isotype control antibodies (eBIoscience) or the small molecule inhibitors: GSK-3 BIO (Calbiochem), SB203580 (Tocris), LY294002 (Sigma), and PD98059 (Cell Signaling) was performed 1 h before stimulation.
Recombinant adenoviral constructs and infection
The adenoviral constructs were kindly provided by Michael Berens (AdFN14) 20 and Thomas Braun (Ad-GFP). 21 The virus titer was determined through direct immunofluorescence staining for adenovirus hexon protein (Imagen Adenovirus; DAKO). Adult cardiomyocytes were infected with the indicated adenoviruses at 100 multiplicity of infection (m.o.i.) 1 day after isolation and stimulated 48 h later.
Immunofluorescence staining
Staining was performed as described previously. 18, 19 Primary antibodies:
rat monoclonal anti-BrdU, mouse monoclonal anti-sarcomeric actinin (both 1:100, Abcam), rabbit polyclonal anti-H3P (1:100, Upstate), rabbit polyclonal anti-Troponin I (1:100, Santa Cruz), mouse monoclonal anti-Aurora B, AIM-1 (1:250, BD Transduction Laboratories), rabbit polyclonal anti-Ki67 (1:500, Novocastra). Immune complexes were detected with ALEXA 488 or ALEXA 594-conjugated secondary antibodies (1:200, Molecular Probes). DNA was visualized with DAPI (4',6'-diamidino-2-phenylindole, 0.5 mg/mL, Sigma). For BrdU, cells were cultured in 30 mM BrdU, incubated after permeabilization for 30 min in 2 N HCl/1% Triton X-100 and washed three times in PBS.
RT-PCR
Total RNA of rat cardiac ventricles from different developmental stages (E11.5-E20, n ! 10, post-natal days 0 -10, and adult n ! 3) was isolated using Trizol (Invitrogen). RT reaction was performed using the oligo(dT) primer (Qiagen). PCR was performed using the following primer sequences: Tnfrsf12a (FN14): forward 5 0 -CACTGATCC AGTGAGGAGCA-3 0 and reverse 5 0 -AGTGGCATTTCAGTCCATCC -3 0 ; GAPDH: forward 5 0 -CAG AAG ACT GTG GAT GGC CC-3 0 and reverse 5 0 -AGT GTA GCC CAG GAT GCC CT-3 0 .
Western blotting
Cardiac ventricles were homogenized in lysis buffer [20 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM b-glycerolphosphate, 1 mmol Na 3 VO 4 , 1 mg/mL leupeptin (Cell Signaling)] containing 1 mM PMSF and Â1 Protease Inhibitor Cocktail (Roche). Cells were suspended in this buffer. After 15 min incubation on ice, the samples were briefly sonicated and centrifuged at 17 000 g at 48C for 10 min. Nuclear extracts were prepared according to the manufacturer instructions (Pierce). The protein concentration was determined using BioRad DC Protein Assay according to manufacturer's protocol (BioRad). Equal amount of proteins were resolved by 12% Novex Bis-Tris Gels (Invitrogen) and blotted on nitrocellulose membranes (Protran w ). Membranes were blocked with 5% non-fat dry milk in Tris-buffered saline (TBS) [10 mM Tris-HCl (pH 7.5), 150 mM NaCl] with 0.1% Tween for 1 h at RT and incubated with primary antibodies diluted 1:1000 in 5% milk/TBS/T and/or 5%BSA/TBS/T over night at 48C: rabbit anti-Cyclin D2 (Santa-Cruz), mouse anti-GSK-3b (BD Transduction Laboratories), rabbit anti-phospho-GSK-3b (S9), rabbit anti-beta-catenin, rabbit anti-TWEAK/FN14 receptor, rabbit anti-pan-actin, rabbit phospho anti-ERK antibody, mouse total anti-ERK, rabbit phopsoho anti-AKT, rabbit total anti-AKT (1:1000) (all Cell Signaling), rabbit anti-Ki67 (1:100) (Abcam), mouse anti-KIP/p27 (1:2500), rabbit anti-H3P (1:500), rabbit anti-dephospho-b-catenin (all from Upstate). Antigen-antibody complexes were visualized using horseradish peroxidase-conjugated secondary antibodies (Amersham) and SuperSignalw ECL detection system (BioRad).
RNA interference
For siRNA-mediated FN14 knockdown cardiomyocytes were transfected by electroporation 22 with 100 nM of siRNAs designed by
Qiagen against FnN14 rat mRNA siRNAFN14a: CTG GAG CGC GGA CCT CGA CAA. Transfection of experimental and control siRNAs was performed by electroporation according to the manufacturer's instructions (Amaxa). All Stars Negative Control siRNA (Qiagen) was used as a negative control.
Statistical analysis
For immunofluorescense analyses 400 -500 of neonatal cardiomyocytes and 200 -300 of adult cardiomyocytes in five random fields of two different subpopulations were counted per experiment. Data of at least three independent experiments are expressed as mean + SEM. The results were analysed by GraphPad Prism (version 4.00, GraphPad Software Inc.). Statistical significance was determined using a Student's t-test. Values of P , 0.05 were considered statistically significant.
Results
TWEAK induces proliferation of neonatal cardiomyocytes
To determine whether TWEAK can induce proliferation in neonatal cardiomyocytes, we performed a dose response analysis utilizing BrdU incorporation assays. Seventy-two hours stimulation with different concentrations of TWEAK recombinant protein in the presence of BrdU (last 48 h) demonstrated that TWEAK could induce DNA synthesis with a maximum effect at 100 ng/mL. Quantification analysis of immunofluorescence stainings for BrdU and a-sarcomeric actinin revealed a 6.2-fold increase in DNA synthesis after TWEAK stimulation compared with unstimulated cells (38.9 + 3.2% vs. 6.5 + 0.7%, n ¼ 3, P , 0.0001) ( Figure 1A and B).
Moreover, at this concentration we observed also an increased expression of Cyclin D2, a known inducer of cardiomyocyte proliferation, 23, 24 and of the proliferation marker Ki67. 25 In contrast,
TWEAK induced the suppression of the cell cycle inhibitor p27/ KIP1 ( Figure 1C ).
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To further assess whether TWEAK is sufficient to promote mitosis in neonatal cardiomyocytes, we performed immunofluorescence stainings for H3P, a mitosis marker. 27 TWEAK stimulation resulted in a 5.5-fold increase of H3P-positive cardiomyocytes (1.6 + 0.15% vs. 0.29 + 0.01%, n ¼ 3, P , 0.001) ( Figure 1D and E). These data demonstrate that TWEAK promotes cell cycle progression into mitosis in neonatal cardiomyocytes. However, during post-natal development, mammalian cardiomyocytes frequently undergo karyokinesis (nuclear division) without cytokinesis (cell division), and 60% of human and 85% of rat adult cardiomyocytes are binucleated. 28 To test whether TWEAK induces cardiomyocyte division, we assayed for cytokinesis using immunofluorescence staining for Aurora B, a marker of the central spindle (Figure 2A , arrow) and the mid-body ( Figure 2A , arrow head) 29 and Troponin I. In addition, we performed cell density experiments ( Figure 2B ). We determined cell numbers at day 0 (frame A: 7, frame B: 6) from phase contrast pictures. After 8 days, the same frames were re-evaluated by immunofluorescence to determine the number of cardiomyocytes. Frame A contained 12 and frame B 9 cardiomyocytes (Troponin I-positive). From this data and the previous DNA synthesis, mitosis, and cytokinesis experiments, we conclude that TWEAK induces cardiomyocyte proliferation. To further verify this conclusion we conducted cell count experiments. These data revealed that TWEAK stimulation resulted in significant increased cardiomyocyte numbers after 8 days of stimulation (2.2-fold, n ¼ 3, P , 0.05) ( Figure 2C ). Taken together, these data demonstrate that TWEAK induces proliferation of post-natal cardiomyocytes.
TWEAK-induced DNA synthesis is FN14-dependent
To determine whether TWEAK induces DNA synthesis via FN14 signalling, we blocked this pathway using blocking antibodies and siRNA before neonatal cardiomyocytes were stimulated with TWEAK for 72 h (48 h BrdU labelling). TWEAK induced in the presence of the isotype (Mouse IgA) control antibody DNA synthesis (43.6 + 1.2% vs. 6.9 + 1.1%, n ¼ 3, P , 0.001). The presence of ITEM-2, an antibody that is known to block the interaction between TWEAK and FN14, abolished the effect of TWEAK-induced BrdU incorporation on DNA synthesis (6.6 + 0.8%, n ¼ 3, P , 0.0001) ( Figure 3A) . In an alternative approach, FN14 siRNA was electroporated into cardiomyocytes directly after isolation in order to knockdown FN14 expression. siRNAmediated knockdown of FN14 was verified by western blot analysis at days 0 (48 h after seeding) and 2 (48 h after stimulation), respectively ( Figure 3B ). FN14 knockdown resulted in a significant decrease of TWEAK-induced BrdU incorporation (18.4 + 4.9%, n ¼ 3) compared with control siRNA-transfected cells (36.7 + 5.3%, n ¼ 3, P , 0.05) ( Figure 3C ). Taken together, our data demonstrate that FN14 signalling mediates the effect of TWEAK on DNA synthesis, which is a prerequisite for cell proliferation.
TWEAK-dependent signalling pathways targeting induction of DNA synthesis
Short-term TWEAK stimulation resulted in phosphorylation of ERK1/2 (Thr202/Tyr204) ( Figure 4A ), AKT (S473), a downstream target of phosphatidylinositol 3-kinase (PI3K) ( Figure 4B) , and GSK-3beta (S9) kinases ( Figure 4D ). TWEAK-induced phosphorylation of GSK-3beta resulted in its degradation, which in turn led to stabilization and accumulation of total beta-catenin ( Figure 4D ) and accumulation of dephosphorylated beta-catenin in the nucleus ( Figure 4E ). In contrast, we observed that p38 MAP kinase phosphorylation (Thr180/Tyr182) was not affected by TWEAK ( Figure 4C ). To explore the role of ERK, PI3K/Akt, and GSK-3beta signalling in TWEAK-induced proliferation, we used specific inhibitors of indicated signalling pathways: LY294002 (PI3 Kinase inhibitor), PD98059 (an inhibitor of MEK1 and MAP kinase cascade activation), 6-bromoindirubin-3 0 -oxime (BIO, an inhibitor of GSK-3), and SB203580 (an inhibitor of p38-MAPK pathway). Pre-treatments with ERK and PI3K inhibitors abolished the positive effect of TWEAK on DNA synthesis. Inhibition of ERK1/2 and PI3K kinases caused a marked decrease in the number of BrdU-positive cardiomyocytes (41.5 + 1.9, P . 0.05, n ¼ 3 compared with 8.2 + 1.8%, P , 0.0002 and 7.4 + 1.2%, P , 0.0001, respectively). However, inhibition of p38 MAP kinase did not affect TWEAK-induced DNA synthesis (45.8 + 2.2% compared with control 41.5 + 1.9, P . 0.05, n ¼ 3) (Figure 5A and B) . Inhibition of GSK-3beta with BIO induced cardiomyocyte proliferation as previously reported. 30 However, combination of GSK-3beta inhibitor BIO and TWEAK did not show a cumulative effect on DNA synthesis in neonatal cardiomyocytes (BIO 67.5 + 1.6% vs. BIO þ TWEAK 69.1 + 1.7%, P . 0.05, n ¼ 3) ( Figure 5A ). Summarizing the results above we propose that TWEAK induces PI3K, ERK, and GSK-3beta signalling pathways that cooperatively interplay to promote cardiomyocyte proliferation. 
TWEAK signalling induces cell cycle re-entry in adult cardiomyocytes
In contrast to neonatal cardiomyocytes, TWEAK induced less than 0.1% of adult cardiomyocytes to incorporate BrdU (data not shown). Interestingly, we observed that in comparison to neonatal cardiomyocytes FN14 expression levels were downregulated in adult cardiomyocytes (Figure 6A -C ) . RT -PCR analysis indicated that FN14 mRNA expression in rat heart ventricles increased from E11 to E14 to reach its maximum and declined after birth ( Figure 6A) . Western blot analyses of protein extracts from isolated rat heart ventricles or isolated cardiomyocytes (E17, P3, and adult) confirmed on protein level that FN14 expression levels were downregulated in adult cardiomyocytes ( Figure 6B and C ) . Thus, we hypothesized that the responsiveness of adult cardiomyocytes to TWEAK is low or absent due to reduced FN14 expression levels.
To test our hypothesis, we overexpressed FN14 in adult cardiomyocytes using adenovirus (AdFN14). We observed that DNA synthesis in adult cardiomyocytes expressing AdFN14 could be significantly induced by the addition of TWEAK (21.6 + 1.7% after 3 days, P , 0.002 and 37.7 + 1.2%, P , 0.001 after 6 days, n ¼ 3) (Figure 6D -G) . We also observed that overexpression of FN14 receptor alone induces DNA synthesis in adult cardiomyocytes (7.3 + 1.1% after 3 days and 22.9 + 2.2% after 6 days, n¼3), which could be rationalized due to the presence of endogenous TWEAK protein in adult rat cardiomyocytes (see Supplementary material online, Figure S1 ). Control AdGFP infected cells in the presence of TWEAK showed no significantly increased DNA synthesis activity compared with uninfected cells (less than 0.1%, Figure 6F and G).
From above presented experiments, it becomes clear that the initial step of cell proliferation, namely DNA synthesis, could not be activated by TWEAK in adult cardiomyocytes due to lack of its receptor (FN14). Interestingly, switching on the TWEAK/ FN14 axis activated not only DNA synthesis, but also resulted in the expression of the proliferation marker Ki67 ( Figure 6H ). Taken together our data indicate that FN14/TWEAK interplay is potent for efficient cell cycle re-entry in adult cardiomyocytes.
Discussion
Our study identifies a previously uncharacterized function of TWEAK/FN14 signalling in regulating mammalian cardiomyocyte proliferation. This is important as it has recently been shown that induction of cardiomyocyte proliferation has the potential to repair the heart after injury. 31 TWEAK as well as FN14 is highly upregulated after injury or during disease, like in the brain after focal cerebral ischaemia 32, 33 and in skeletal muscle after cardiotoxin injection. 7 In addition, TWEAK/FN14 signalling plays a beneficial role in coordinating cell expansion and acute inflammation contributing to tissue repair. 34 Detailed analyses of TWEAK-and FN14-deficient mice have revealed that primary myoblasts from FN14-deficient mice display significantly reduced proliferative capacity and altered myotube formation. 7 TWEAK-deficient mice with acute kidney injury displayed less tubular cell proliferation. 10 These developmental studies support the previous findings 6 -10 that TWEAK is a multipotent pro-proliferative factor. Recently, first studies have been published regarding the role of TWEAK in the heart. Jain et al. 35 have shown that FN14 is expressed in hearts of foetal as well as adult mice but mentioned that TWEAK-deficient mice exhibit no cardiac phenotype. 35 In contrast, transgenic mice overexpressing TWEAK exhibited overt cardiomyocyte hypertrophy but not apoptosis. A recent report from Chorianopoulos et al. 36 demonstrated that both TWEAK and FN14 are upregulated in the remodelling myocardium after myocardial infarction. Our data demonstrate that TWEAK can induce neonatal cardiomyocyte proliferation. Stimulation resulted in the upregulation of proteins known to be necessary for cardiomyocyte proliferation (Ki67, H3P, Cyclin D2, Aurora B). We observed DNA synthesis, mitosis, and cytokinesis of cardiomyocytes and could demonstrate an increase in cardiomyocyte numbers. The effect of TWEAK is mediated via FN14 receptor as demonstrated by siRNA and blocking experiments. The present study reveals the importance of ERK, PI3K/Akt, and GSK-3beta pathways for TWEAK-induced cardiomyocyte proliferation. The blocking of one of these pathways alone completely diminished TWEAK-induced DNA synthesis, which suggests that all of them cooperate together. These pathways are known to be important for cardiomyocyte proliferation. Previously, it has been shown that the GSK-3 signalling pathway regulates cardiomyocyte proliferation during development. 37 Also it has been shown that GSK-3beta inhibition by a small molecule approach induces post-natal cardiomyocyte proliferation. 30 In addition, we 2 and others 4 have previously demonstrated that induction of PI3K/Akt signalling pathway plays an important role in regulating cardiomyocyte proliferation. Taken together, our data provide evidence that TWEAK is a novel regulator of cardiomyocyte proliferation via the FN14 receptor and the downstream ERK, PI3K/Akt, and GSK-3beta signalling pathways. In contrast to neonatal cardiomyocytes, TWEAK stimulation did only induce DNA synthesis in a few adult cardiomyocytes. Our data suggest that this is due to the downregulation of the receptor of TWEAK, FN14. Similar observations have been made for FGF1, 38 periostin, 39 and neuregulin. 40 ). Interestingly, overexpression of FN14 enabled us to induce DNA synthesis in adult cardiomyocytes with TWEAK at similar levels as observed in neonatal cardiomyocytes. This suggests that not a small subpopulation but the majority of adult cardiomyocytes can re-enter the cell cycle.
Others and we have shown that complete cell division can be induced in adult cardiomyocytes. 2 -4 However, in contrast to neonatal cardiomyocytes, induction of proliferation or marked DNA synthesis in adult cardiomyocytes has previously not been achieved. And even though evidence has been provided for the possibility to regenerate the heart by inducing cardiomyocyte proliferation, we are just at the beginning. Thus it is essential to better understand the mechanisms to regulate cardiomyocyte proliferation to establish a robust clinical therapy for ischaemic heart disease. It will be important to test in future experiments if also the overexpression of receptors for FGF1, periostin, and neuregulin can promote adult cardiomyocyte proliferation. The recent finding that transgenic mice overexpressing ErbB4, a neuregulin receptor, increased the amount of mononucleated cardiomyocytes in cooperating BrdU in vivo 3-fold 3 supports our hypothesis that signalling and cell cycle re-entry can be restored in adult cardiomyocytes. In addition to DNA synthesis, TWEAK induces also the expression of Ki67. Ki67 has been used in histochemistry to distinguish quiescent cells (G0) from active 'cycling' cells and therefore is often used as a proliferation marker. However, Ki67 expression does not mean that these cells will indeed enter mitosis and undergo cell division. Thus, we determined whether TWEAK stimulation resulted in cell cycle progression beyond S-phase (DNA synthesis) but we did not observe any mitosis or cytokinesis in our assays (data not shown).
It will be interesting to determine in experimental animal models of acute myocardial infarction whether activation of the TWEAK/ FN14 signalling can induce in vivo cardiomyocyte proliferation and can improve heart function. It appears that simply providing TWEAK will not be sufficient as Jain et al. 35 have recently described that transgenic overexpression resulted in the development of cardiac dysfunction and failure. 35 It is possible that the outcome of TWEAK signalling depends on the FN14 receptor density. Thus, it will be important to combine TWEAK stimulation with FN14 overexpression in future in vivo experiments. Taken together, TWEAK/FN14 signalling is a potent inducer of cell cycle re-entry in neonatal and adult cardiomyocytes. Furthermore, TWEAK can induce proliferation in neonatal but not adult cardiomyocytes. We will focus in the future on elucidating pathways that allow us to push adult cardiomyocytes after TWEAK/ FN14-induced DNA synthesis into mitosis and through cell division. In conclusion, our and other recent findings raise the hope that understanding the TWEAK/FN14 signalling pathway may result in the future in better treatments for paediatric and adult heart patients.
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